DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* CERENIS THERAPEUTICS *


 

2004 - Midi-Pyrénées
Labège
(near Toulouse)
www.cerenis.com

 

Discovery, Drugs
Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars
Mission: to discover, develop and market next generation HDL therapies
Clients: Prescribers
info@cerenis.com

Age: 12 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier]
Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo]
Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer]
Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers]
Med.Dir.-CMO: Paolini (John F.) [M.D., Ph.D., ex-Merck US, Bayer]
BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical]
Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO

Turnover (M€) : n.a.
Total funding (M€) : 117.0
Last funding (M€) : 50.0
Focus : Cardiovasc
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .03 Clinical trial (phase II) for CER-001, in acute coronary syndrome (beginning) CLIN [6 years]
2010 .07 3rd round-financing : 40.0 M€, half by FSI, half by previous shareholders, Sofinnova Partners, HealthCap, Alta Partners et TVM Capital, EDF Ventures, Orbimed and Daiwa (completed in October by 10.0 M€ additional from Irdi-IXO and private investors) RFINC [6 years]
2010 .05 Clinical trial (phase I) for CER-001, a new drug for acute coronary syndrome (completed) CLIN [6 years]
2010 .06 Financing (no interest loan) : 10.7 M€ by OSEO Innovation, shared with Novasep, to finance the development of CER-001, an HDL-mimetic innovative drug DEBT [6 years]
2009 .02 Financing (no interest loan) : 2.5 M€ by OSEO Innovation, to finance ongoing clinical development of HDL-related products for the treatment of cardiovascular and metabolic diseases DEBT [4 years]
2008 .05 Clinical trial (phase I) for CER-002, a peroxisome proliferator-activated receptor (PPAR) delta specific agonist (completed) CLIN [4 years]
2006 .11 2nd round-financing : 42.0 M€, led by TVM Capital, with Orbimed and previous shareholders (53.5 MUS$) RFINB [2 years]
2005 .08 1st round-financing : 25.0 M€, by Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures RFINA [1 year]
2004 .05 Company founded by Jean-Louis Dasseux and William Brinkerhoff ORGF [0 year]

Actualisation / Updating: 23-Feb-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende